Jiyoon Park1, Eunice Yewon Lee2, Jie Li3, Mi Jung Jun4, Eileen Yoon5, Sang Bong Ahn6, Chuanli Liu3, Hongli Yang3, Fajuan Rui3, Biyao Zou2, Linda Henry2, Dong Hyun Lee4, Dae Won Jun7, Ramsey C Cheung2,8, Mindie H Nguyen2. 1. Department of Internal Medicine, Santa Clara Valley Medical Center, San Jose, California, USA. 2. Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA. 3. Department of Infectious Disease, The Provincial Hospital Affiliate of Shandong University, Jian, China. 4. Division of Gastroenterology, Department of Internal Medicine, Good Gang-An Hospital, Busan, Republic of Korea. 5. Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul, Republic of Korea. 6. Department of Internal Medicine, Nowon Eulji Medical Center, Eulji University College of Medicine, Seoul, Republic of Korea. 7. Department of Gastroenterology, Hanyang University, Seoul, Republic of Korea. 8. Division of Gastroenterology and Hepatology, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA.
Abstract
BACKGROUND: NAFLD incidence, NASH prevalence, NAFLD fibrosis prevalence, incidence of metabolic comorbidities, and mortality data in the NAFLD population remain limited. AIMS: We used a meta-analytic approach to "stage" NAFLD among the Korean population. METHODS: We searched PubMed, Embase, Cochrane Library, and KoreaMed from inception until June 29, 2019, and calculated pooled estimates via the random-effects model. RESULTS: We screened 1,485 studies and analyzed 191 eligible studies: 179 (3,556,579 participants) for NAFLD prevalence and outcome analysis and 32 (1,089,785 participants) for NAFLD incidence analysis. NAFLD prevalence was 31.46% overall and 50-60% in those with metabolic risks. The incidence (per 1,000 person-years) of NAFLD was 42.8 overall and 70-77% in those with metabolic risk. The incidence (per 1,000 person-years) of new-onset T2DM, hypertension, cardiovascular disease, and chronic kidney disease was found to be 16.9, 47.9, 100.6, and 13.9, respectively. From biopsy data, 30.21% of the NAFLD population had moderate-to-severe steatosis (9 studies, 2,461 participants) and 52.27% had NASH (7 studies, 1,168 participants) and 85.41% had fibrosis <stage 2 (8 studies, 1,995 participants). All-cause mortality was 2.6 (1.3 if without malignancy) per 1,000 person-years. CONCLUSIONS: The overall prevalence of NAFLD was 31.46% with an incidence rate of 42.8 per 1,000 person-years. NASH prevalence was 52% but <15% had significant fibrosis. The prevalence and incidence of nonliver comorbidities was high especially for cardiovascular disease incidence. The burden of NAFLD is high in Korea. Health policy efforts need to be directed towards reversing the course of NAFLD disease.
BACKGROUND: NAFLD incidence, NASH prevalence, NAFLD fibrosis prevalence, incidence of metabolic comorbidities, and mortality data in the NAFLD population remain limited. AIMS: We used a meta-analytic approach to "stage" NAFLD among the Korean population. METHODS: We searched PubMed, Embase, Cochrane Library, and KoreaMed from inception until June 29, 2019, and calculated pooled estimates via the random-effects model. RESULTS: We screened 1,485 studies and analyzed 191 eligible studies: 179 (3,556,579 participants) for NAFLD prevalence and outcome analysis and 32 (1,089,785 participants) for NAFLD incidence analysis. NAFLD prevalence was 31.46% overall and 50-60% in those with metabolic risks. The incidence (per 1,000 person-years) of NAFLD was 42.8 overall and 70-77% in those with metabolic risk. The incidence (per 1,000 person-years) of new-onset T2DM, hypertension, cardiovascular disease, and chronic kidney disease was found to be 16.9, 47.9, 100.6, and 13.9, respectively. From biopsy data, 30.21% of the NAFLD population had moderate-to-severe steatosis (9 studies, 2,461 participants) and 52.27% had NASH (7 studies, 1,168 participants) and 85.41% had fibrosis <stage 2 (8 studies, 1,995 participants). All-cause mortality was 2.6 (1.3 if without malignancy) per 1,000 person-years. CONCLUSIONS: The overall prevalence of NAFLD was 31.46% with an incidence rate of 42.8 per 1,000 person-years. NASH prevalence was 52% but <15% had significant fibrosis. The prevalence and incidence of nonliver comorbidities was high especially for cardiovascular disease incidence. The burden of NAFLD is high in Korea. Health policy efforts need to be directed towards reversing the course of NAFLD disease.
Authors: Rod S Taylor; Rebecca J Taylor; Sue Bayliss; Hannes Hagström; Patrik Nasr; Jorn M Schattenberg; Masatoshi Ishigami; Hidenori Toyoda; Vincent Wai-Sun Wong; Noam Peleg; Amir Shlomai; Giada Sebastiani; Yuya Seko; Neeraj Bhala; Zobair M Younossi; Quentin M Anstee; Stuart McPherson; Philip N Newsome Journal: Gastroenterology Date: 2020-02-04 Impact factor: 22.682
Authors: Zobair M Younossi; Mazen Noureddin; David Bernstein; Paul Kwo; Mark Russo; Mitchell L Shiffman; Ziad Younes; Manal Abdelmalek Journal: Am J Gastroenterol Date: 2020-12-07 Impact factor: 10.864
Authors: Wisit Cheungpasitporn; Charat Thongprayoon; Karn Wijarnpreecha; Donald G Mitema; Michael A Mao; Pitchaphon Nissaisorakarn; Alexander Podboy; Wonngarm Kittanamongkolchai; Ankit Sakhuja; Stephen B Erickson Journal: J Evid Based Med Date: 2017-05-21
Authors: Rebekka Pohl; Laura Eichelberger; Susanne Feder; Elisabeth M Haberl; Lisa Rein-Fischboeck; Nichole McMullen; Christopher J Sinal; Astrid Bruckmann; Thomas S Weiss; Michael Beck; Marcus Höring; Sabrina Krautbauer; Gerhard Liebisch; Reiner Wiest; Josef Wanninger; Christa Buechler Journal: Mol Cell Biochem Date: 2022-04-21 Impact factor: 3.842